It was more than 200 years ago that Edward Jenner became the first person to successfully develop a vaccine.1 Since his milestone vaccine against smallpox, no medical achievement has done more to save lives and improve quality of life than the simple act of vaccination.2 The science Jenner used in that first vaccine is still widely used today, but there is more to do. There are still diseases for which no vaccine exists. New technologies are now allowing us to explore therapeutic, as well as preventive, vaccination for the first time. This means vaccines may become commonly used to treat existing conditions, rather than as prevention against illness.
These new technologies have been created as the result of an explosion in our knowledge of the human body, immunology, virology and genomics, and are allowing scientists to develop vaccines for diseases that haven’t previously been vaccine preventable. Adjuvant Systems, a technology GSK has been working on for more than 20 years, has made it possible to develop vaccines that target specific age groups, such as or older people. As we get older so does our immune system, which means a vaccine may require the boosting effect of an adjuvant to make some types of vaccine work more effectively.